BNET Industries

SurModics Inc.

Market Cap:$398.9M
Last Fiscal Year Sales:$97.0M
  • Public
  • US
Dow Jones Description

SurModics is a leading provider of drug delivery and surface modification technologies to the healthcare industry. In November 2008, we announced a change in our organizational structure into four clinically and market focused business units: Cardiovascular, Ophthalmology, In Vitro Technologies, and SurModics Pharmaceuticals (formerly Brookwood Pharmaceuticals). We believe that this structure will improve the visibility, marketing and adoption of the Companys broad array of technologies within specific markets and help our customers in the medical device, pharmaceutical and life science industries better solve unmet clinical needs. In addition, a new centralized research and development function has been formed to serve the needs of the Companys clinically and market focused business units. SurModics Pharmaceuticals research and development operations remained unchanged. The reorganization change announced in November 2008 resulted in the Company being comprised of new operating segments. ...

Number of Employees 254
Contact Information

9924 W 74th St

Eden Prairie, Minnesota 55344-3523

surmodics.com

(952) 829-2700

NAICS Code Lessors of Nonfinancial Intangible Assets (except Copyrighted Works): 533110

Recent Events

  • Developments for Parkinson's Disease Ignite Investor Enthusiasm

    11/16/09 - Joint Venture / Alliance - View Story

  • SurModics signs license agreement with NuPathe for long-acting delivery (LADTM) technology

    11/03/09 - Joint Venture / Alliance - View Story

  • Barrington Research Downgrades SurModics SRDX to Market Perform

    10/13/09 - Bond / Stock Rating - View Story

  • SurModics enters license and development agreement with Roche and Genentech

    10/07/09 - Joint Venture / Alliance - View Story

  • SurModics Enters Ophthalmic License and Development Agreement with Roche and Genentech

    10/06/09 - Joint Venture / Alliance - View Story

  • Genentech inks licensing deal with SurModics

    10/07/09 - Joint Venture / Alliance - View Story

  • SurModics inks $200M licensing deal with Genetech

    10/06/09 - Joint Venture / Alliance - View Story

  • SRDX: License and Development Agreement with Roche and Genentech

    10/06/09 - Joint Venture / Alliance - View Story

  • UPDATE 1-Church & Dwight settles with Abbott Labs, SurModics

    9/24/09 - Legal Settlement - View Story

  • SurModics Reports Third Quarter 2009 Results

    7/29/09 - Financial Announcement - View Story

News & Analysis

finance and surmodics inc. - All News and Analysis

advertisement
     SRDX $23.09 +0.34 (1.49% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 139,821
Shares Outstanding 17.48M
Market Cap 403.5M
Year High 31
Year Low 15.96
Earnings Per Share 2.15
P/E Ratio 10.74
Dividend N/A
Yield N/A
IndustryTop Rated
advertisement